JP2022523355A5 - - Google Patents
Info
- Publication number
- JP2022523355A5 JP2022523355A5 JP2021549216A JP2021549216A JP2022523355A5 JP 2022523355 A5 JP2022523355 A5 JP 2022523355A5 JP 2021549216 A JP2021549216 A JP 2021549216A JP 2021549216 A JP2021549216 A JP 2021549216A JP 2022523355 A5 JP2022523355 A5 JP 2022523355A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound according
- independently selected
- salt
- deuterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808954P | 2019-02-22 | 2019-02-22 | |
| US62/808,954 | 2019-02-22 | ||
| US201962936358P | 2019-11-15 | 2019-11-15 | |
| US62/936,358 | 2019-11-15 | ||
| PCT/US2020/019193 WO2020172516A1 (en) | 2019-02-22 | 2020-02-21 | Compounds and methods of deuterated xanomeline for treating neurological disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022523355A JP2022523355A (ja) | 2022-04-22 |
| JP2022523355A5 true JP2022523355A5 (https=) | 2023-03-09 |
Family
ID=72145029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549216A Pending JP2022523355A (ja) | 2019-02-22 | 2020-02-21 | 神経障害の処置のための重水素化キサノメリンの化合物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220144817A1 (https=) |
| EP (1) | EP3927342A4 (https=) |
| JP (1) | JP2022523355A (https=) |
| CN (1) | CN113507928A (https=) |
| AU (1) | AU2020226870A1 (https=) |
| BR (1) | BR112021016457A2 (https=) |
| CA (1) | CA3131128A1 (https=) |
| WO (1) | WO2020172516A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11534434B2 (en) | 2019-11-15 | 2022-12-27 | Karuna Therapeutics, Inc. | Xanomeline derivatives and methods for treating neurological disorders |
| CN115974863B (zh) * | 2021-10-14 | 2024-12-31 | 南京迈诺威医药科技有限公司 | 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途 |
| US12269818B2 (en) * | 2023-04-24 | 2025-04-08 | Terran Biosciences Inc. | Analogs of xanomeline |
| WO2025174424A1 (en) * | 2024-02-16 | 2025-08-21 | Terran Biosciences Inc. | Analogs of xanomeline, analogs of trospium, and methods of use thereof |
| CN119161338B (zh) * | 2024-11-25 | 2025-06-17 | 嘉兴安帝康生物科技有限公司 | 用作毒蕈碱受体激动剂的四氢吡啶衍生物及其在医药上的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10508028A (ja) * | 1994-10-31 | 1998-08-04 | イーライ・リリー・アンド・カンパニー | 不安を治療する方法 |
| CA2239732A1 (en) * | 1995-12-07 | 1997-06-12 | Eli Lilly And Company | Method for treating pain |
| NZ542690A (en) * | 2003-03-28 | 2009-04-30 | Acadia Pharm Inc | Muscarinic M1 receptor agonists for pain management |
| CA2754203A1 (en) * | 2009-03-05 | 2010-09-10 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| US10265311B2 (en) * | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| PT3061821T (pt) * | 2009-07-22 | 2019-09-05 | PureTech Health LLC | Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos |
| WO2012033956A1 (en) * | 2010-09-08 | 2012-03-15 | Mithridion, Inc. | Cognition enhancing compounds and compositions, methods of making, and methods of treating |
-
2020
- 2020-02-21 JP JP2021549216A patent/JP2022523355A/ja active Pending
- 2020-02-21 EP EP20759391.4A patent/EP3927342A4/en not_active Withdrawn
- 2020-02-21 AU AU2020226870A patent/AU2020226870A1/en not_active Abandoned
- 2020-02-21 CN CN202080014856.8A patent/CN113507928A/zh active Pending
- 2020-02-21 US US17/310,735 patent/US20220144817A1/en not_active Abandoned
- 2020-02-21 BR BR112021016457-0A patent/BR112021016457A2/pt not_active Application Discontinuation
- 2020-02-21 CA CA3131128A patent/CA3131128A1/en active Pending
- 2020-02-21 WO PCT/US2020/019193 patent/WO2020172516A1/en not_active Ceased